AZTA at a glance
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 16 – Nov 22
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
AZTA price history
Loading AZTA and S&P 500 price history…
Loading recent earnings…
Investment thesis
What must happen next
Azenta's installed base of automated storage and repository operations creates recurring services and consumables annuity revenue that underpins durable top-line growth and pricing leverage.StrengtheningMateriality: High
Revenue increased from $551,486,000 (FY2023) to $621,703,000 (FY2026), showing steady top-line expansion. If true, revenue becomes more predictable and margin-accretive over time; if false, growth is lumpy, more capex-dependent, and pricing power is limited.
Watch: Large customers insource sample management (major pharma/biotech build internal repositories).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Revenue increased from $551,486,000 (FY2023) to $621,703,000 (FY2026), showing steady top-line expansion.
Open source ↗Multiomics and gene-synthesis investments are a binary driver: if integration and scale succeed they deliver higher-margin services; if they fail or are commoditized they will keep GAAP operating income weak and intermittently require impairments.HoldingMateriality: High
Operating income swung to a loss of $-174,699,000 in FY2026 from $-26,844,000 in FY2025, reflecting investment, acquisition and restructuring impacts. Success turns Azenta into a higher-margin, growing services company; failure leaves it an acquisition-fed business with volatile operating results and valuation risk.
Watch: Competing gene synthesis players (e.g., Twist Bioscience, Genscript, or larger platforms) dominate scale or price aggressively.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating income swung to a loss of $-174,699,000 in FY2026 from $-26,844,000 in FY2025, reflecting investment, acquisition and restructuring impacts.
Open source ↗Azenta's operations generate positive operating cash flow that can fund organic growth, restructuring and smaller tuck-in M&A without immediate equity dilution.StrengtheningMateriality: Medium
Operating cash flow was $57,506,000 in FY2026 and improved materially from $5,834,000 in FY2023, showing underlying cash generation. Positive cash conversion reduces financing risk and supports reinvestment to scale Multiomics and SRS; a reversal would force dilutive financing or curtailed growth.
Watch: Rapid M&A or capex for scaling gene synthesis could outstrip operating cash and force debt/equity financing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating cash flow was $57,506,000 in FY2026 and improved materially from $5,834,000 in FY2023, showing underlying cash generation.
Open source ↗The market multiple implicitly prices a return to sustained operating profitability and margin expansion; absent clear and durable operating_income improvement, the stock is vulnerable to de-rating.WeakeningMateriality: Medium
FY2026 operating income was a substantial loss of $-174,699,000 (versus smaller losses prior years), while valuation metrics show EV/EBITDA ~55.97 and P/S ~3.47. Investors require visible paths from current large GAAP losses to steady profits; failure to provide that path will compress the multiple and the share price.
Watch: Recurring restructuring, goodwill or asset impairment charges that keep operating_income deeply negative.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2026 operating income was a substantial loss of $-174,699,000 (versus smaller losses prior years), while valuation metrics show EV/EBITDA ~55.97.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Azenta's installed base of automated storage and repository operations creates recurring services and consumables annuity revenue that underpins durable top-line growth and pricing leverage. If true, revenue becomes more predictable and margin-accretive over time; if false, growth is lumpy, more capex-dependent, and pricing power is limited.
Multiomics and gene-synthesis investments are a binary driver: if integration and scale succeed they deliver higher-margin services; if they fail or are commoditized they will keep GAAP operating income weak and intermittently require impairments. Success turns Azenta into a higher-margin, growing services company; failure leaves it an acquisition-fed business with volatile operating results and valuation risk.
Azenta's operations generate positive operating cash flow that can fund organic growth, restructuring and smaller tuck-in M&A without immediate equity dilution. Positive cash conversion reduces financing risk and supports reinvestment to scale Multiomics and SRS; a reversal would force dilutive financing or curtailed growth.
The market multiple implicitly prices a return to sustained operating profitability and margin expansion; absent clear and durable operating_income improvement, the stock is vulnerable to de-rating. Investors require visible paths from current large GAAP losses to steady profits; failure to provide that path will compress the multiple and the share price.
All standing thesis claims
Original report summary
acquisitions and Multiomics investments scale — can generate high-margin, cash-producing lifecycle solutions for life-science customers.
Bull case and bear case
Bull case and bear case for Azenta
Where the evidence on Azenta disagrees: Mixed on the latest evidence (Nov 22, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
Azenta's installed base of automated storage and repository operations creates recurring services and consumables annuity revenue that underpins durable top-line growth and pricing leverage.
Multiomics and gene-synthesis investments are a binary driver: if integration and scale succeed they deliver higher-margin services; if they fail or are commoditized they will keep GAAP operating income weak and intermittently require impairments.
Azenta's operations generate positive operating cash flow that can fund organic growth, restructuring and smaller tuck-in M&A without immediate equity dilution.
Bear case: what the evidence questions
The market multiple implicitly prices a return to sustained operating profitability and margin expansion; absent clear and durable operating_income improvement, the stock is vulnerable to de-rating.
Thesis-Break Engine
Thesis-break watch · Azenta
Loading the break-condition record for Azenta.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Azenta filed an SEC 8-K on 2026-11-10: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Azenta filed an SEC 8-K on 2026-10-30: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedMaterial impairment.
Azenta filed an SEC 8-K on 2026-10-07: Material impairment. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large customers insource sample management (major pharma/biotech build internal repositories).
- Competing gene synthesis players (e.g., Twist Bioscience, Genscript, or larger platforms) dominate scale or price aggressively.
- Rapid M&A or capex for scaling gene synthesis could outstrip operating cash and force debt/equity financing.
- Recurring restructuring, goodwill or asset impairment charges that keep operating_income deeply negative.
AZTA news
Loading headlines…
Financial statements
AZTA income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

